LH-Suppression mit dem GnRH-Antagonisten Cetrotide® 3 mg im Einmalgabe-Protokoll: Offene, prospektive, nicht randomisierte Studie bei 100 Patientinnen im Rahmen einer Superovulation

Abstract

Objective: Cetrotide®, a GnRH-antagonist in comparison to GnRH-agonists leads to immediate LH-suppression of the endogenous pituitary LH-release without a so-called flare-up effect of the GnRH-agonist. Cetrotide® is the first GnRH-antagonist in Germany launched in May 1999 available for single dose protocol (3 mg) and multiple dose protocol (0.25mg). However, so far there is only little experience with the single dose protocol (3 mg) under everyday circumstances. In a post-surveillance study 100 cycles with the single dose protocol (3 mg) will be documented. Methods: The experiences of an open, prospective non-randomised study in superovulation cycles in 100 patients treated using a single dose protocol with 3 mg are reported. Results: Out of the 100 cycles 46% first and 54% follow-up cycles (78% IVF and 22% ICSI) have been documented. During a mean of 11.2 stimulation days 8.2 follicles ≥10 mm developed with serum estradiol concentration of 1049.4 pg/ml (3851 pmol/l) on the day of hCG injection. A mean of 6.1 oocytes were retrieved in 87 cycles. 72 patients had an embryotransfer with a biochemical pregnancy rate (hCG > 100 I.U./I) of 34.7% and a clinical pregnancy rate of 25.0%. OHSS II° was reported in 2.8% of the cycles, no OHSS III° was reported.